Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression

Journal of Affective Disorders(2025)10.1016/j.jad.2025.02.003Source: DataRank Database

Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression is a research paper published in Journal of Affective Disorders (2025). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 4.82)OA: greenTopics (32)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Colin Xu ORCID,Jay D. Amsterdam,Thomas T. Kim ORCID

Live enrichment

PubMed:39904463 PMC:PMC11867850 OpenAlex:https://openalex.org/W4407069728

NIH National Institute of General Medical Sciences

Grant: P20GM104420

National Institutes of Health

University of Pennsylvania

FWCI

4.82

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11867850/

publisherhttps://api.elsevier.com/content/article/PII:S0165032725001909?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0165032725001909?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39904463

Fields of Study

Treatment of Major DepressionTryptophan and brain disordersNeurotransmitter Receptor Influence on Behavior

MeSH Terms

Administration, CutaneousAdministration, OralAdultAgedAntidepressive Agents, TricyclicFemaleHumansMaleMiddle AgedMonoamine Oxidase InhibitorsSelegilineTreatment OutcomeDepressive Disorder, Treatment-Resistant

Keywords

SelegilineMonoamine oxidaseTricyclicDepression (economics)TransdermalMedicineMonoamine oxidase inhibitorPharmacologyAntidepressantTricyclic antidepressantPsychiatryInternal medicineAnxietyChemistryEnzymeBiochemistry

Sustainable Development Goals

SDG 0: Good health and well-being